OcuTerra
MA - BostonBiotechnology
Focus: OcuTerra is a biotechnology company focused on diabetic eye disease treatment, headquartered in Boston and operating in the ophthalmology space. The company is in early-stage development with a focused pipeline targeting unmet needs in retinal diseases.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About OcuTerra
AI assessmentNot HiringNo open roles listed right now. Follow OcuTerra to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SF0166 Topical Ophthalmic Solution
Diabetic Macular EdemaClinical Trials (1)
NCT02914613Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)
Phase 1/2Help build intelligence for OcuTerra
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.